Loading...
Epidemiological Challenges in Rare Bleeding Disorders: FVIII Inhibitor Incidence in Haemophilia A Patients—A Known Issue of Unknown Origin
There is a broad range of factor products approved in Germany for haemophilia A treatment. Since the introduction of recombinant coagulation factor VIII (FVIII) products in the 1990s, there has been substantial debate whether there is a difference in inhibitor incidence between single FVIII products...
Na minha lista:
| Udgivet i: | Int J Environ Res Public Health |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7795862/ https://ncbi.nlm.nih.gov/pubmed/33396748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijerph18010225 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|